Navigation Links
Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
Date:11/11/2009

l of cancer cells. Oncothyreon currently expects to complete patient enrollment in its Phase 1 trial of PX-478 in the fourth quarter of 2009. In addition, pre-clinical data concerning the activity of PX-478 in diffuse large B-cell lymphoma cells will be presented at the American Society of Hematology meeting in early December 2009.

Conference Call and Webcast

Oncothyreon's management will discuss the Company's third quarter 2009 financial results and provide a business update during a conference call beginning at 4:30 p.m. ET/1:30 p.m. PT today, Wednesday, November 11, 2009. To listen to a webcast of the discussion, visit www.oncothyreon.com.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of our current results and future prospects, this release may contain statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, the following: our expectations regarding future expenses; clinical and pre-clinical development activities, including our plans to substantially complete the pre-clinical development of BGLP40 in 2010, our goal to initiate c
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncothyreon announces webcast of third quarter 2009 financial results conference call
2. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
3. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
4. Oncothyreon reports second quarter 2009 financial results
5. Oncothyreon announces closing of $15.0 million registered direct financing
6. Oncothyreon announces webcast of second quarter 2009 financial results conference call
7. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
8. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
9. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
10. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
11. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report defines and ... and forecast of revenue. This market is estimated to ... by 2019, at a Compound Annual Growth Rate (CAGR) ... the TOC of the Asia-Pacific Speech Analytics market report ... It also provides a glimpse of the segmentation in ...
(Date:10/19/2014)... Asian Orthopedic braces and support systems report defines and segments ... revenue. The Orthopedic braces and support systems market in Asia ... at a developing CAGR of 4.4% from 2013 to 2018. ... and support systems market, to get an idea of the ... segmentation of orthopedic braces and support systems market in the ...
(Date:10/19/2014)... October 19, 2014 According to ... (Access Points; WLAN Controllers; Wireless gateways)]- Global Advancements, ... segments the global Outdoor Wi-Fi market with analysis ... report MarketsandMarkets also identifies the drivers and the ... the trends, opportunities and challenges. , Browse 65 ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The ... defines and segments the bio-based advanced phase change ... of revenue. , Browse through the TOC of ... report to get an idea of the in-depth ... the segmentation in the Asia-Pacific bio-based advanced phase ...
Breaking Biology Technology:The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 4The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4
... Coverage of Hepatitis C Patients Is Skewed Towards ... Coverage in the General Population, According to a ... 12 Decision Resources, one of the world,s ... and healthcare issues, finds that hepatitis C virus ...
... Pharmaceutical,Inc. (Nasdaq: BMRN ) announced today ... the Riquent(R) Phase 3 ASPEN trial, the Independent ... the trial is,futile. BioMarin and partner La ... the data and evaluate all of the clinical ...
... Inc. announced a vibrant new addition today to their ... Harbor, Maine, was unanimously elected by the Board to ... a successful biotechnology professional with 20 years of experience ... of career accomplishments that include establishing and launching successful ...
Cached Biology Technology:Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 2Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 3Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 2Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 3SenesTech, Inc. Appoints Susan Airhart to Board of Directors 2
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
(Date:10/14/2014)... a new kind of stem cell that can become either ... vessels, according to a study published today in the journal ... cell type contradicts current theory on how organs arise from ... origins of, and future treatment for, liver cancer., Thanks to ... complex being made up of more than 200 cell types. ...
(Date:10/14/2014)... Scientists from The Scripps Research Institute (TSRI) have been ... (NIH) to lead an investigation of Lassa fever virus, ... The study aims to understand how Lassa fever virus ... survive the inflection. , "The ultimate goal is ... Lassa fever virus causes disease and develop new treatments ...
Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... obese and hope to be a father, here,s another ... inherit your waistline or metabolic disorders. That,s because scientists ... who did not show any signs of diabetes, passed ... Sons don,t entirely dodge this genetic bullet eitherboth ...
... and the National Institutes of Health have obtained ground-breaking new ... play a role in the development of cancer cells. The ... and have just been published in Journal of Biological ... of proteases to force their way into the body., In ...
... security scanners with higher sensitivity could result from ... waves). Published in the journal Advanced ... structure which traps terahertz waves in tiny (micro-scale) ... currently possible. Terahertz waves, which are electromagnetic ...
Cached Biology News:Obese dads pass on predisposition to obesity and metabolic disorders to their kids 2Molecular discovery puts cancer treatment in a new perspective 2Molecular discovery puts cancer treatment in a new perspective 3Trapping T-rays for better security scanners 2
Ezrin/Radixin/Moesin Antibody...
Rabbit anti-NFkB p105/p50 (Ser529) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
... polyclonal to Taura Syndrome Virus ... for all tested applications). ... peptide: VTNSEGSTIL MNDIPITNQN VVLSKNVTDN LFEVQDQALI ... to N terminal amino acids ...
Biology Products: